We emphasize that, although the literature and our findings provide the rationale for attempts to exploit PKC as a target for novel forms of treatment of GBM, our incomplete understanding of the cell- and tissue-specificity of the different PKC isoforms may lead to unexpected and/or undesired results in clinical practice becoming important subjects for further studies. The gene discussed is PRRT2; the disease is glioblastoma.